Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 16/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 17/20 | 0.50 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4097472 | 0.87 | ADORA2A (0.53) | ADORA1ADORA2ANUDT1 | |
| SCHEMBL4107186 | 0.87 | ADORA2A (0.63) | ADORA1ADORA2AATRADORA2B | |
| SCHEMBL4775381 | 0.85 | MAOB (0.43) | ADORA1ADORA2AATR | |
| SCHEMBL4101040 | 0.83 | ADORA2A (0.44) | ADORA1ADORA2ANUDT1ADORA2B | |
| SCHEMBL4097613 | 0.82 | ADORA2A (0.60) | ADORA1ADORA2ANUDT1ADORA2B | |
| SCHEMBL4113320 | 0.81 | ADORA2A (0.58) | ADORA1ADORA2ANUDT1ADORA2B | |
| SCHEMBL4110099 | 0.81 | ADORA2A (0.52) | ADORA1ADORA2ANUDT1 | |
| SCHEMBL4107477 | 0.81 | ADORA2A (0.49) | ADORA1ADORA2ANUDT1ATR | |
| SCHEMBL4115816 | 0.80 | GHSR (0.44) | ADORA2AATR | |
| SCHEMBL4107610 | 0.80 | SCN9A (0.53) | ADORA1ADORA2ANUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2009-10-08 | — | — | US | claimed |
| US-8338435-B2 | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2009-10-08 | — | — | US | disclosed |
| WO-2008009076-A2 | SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | PNPO, PNP, DPYD | ADORA1 163/4885ADORA2A 165/4885NUDT1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.